Last updated: February 24, 2026
What is the scope of patent AU2017272232?
Patent AU2017272232 covers a pharmaceutical invention related to the treatment of a specific disease or medical condition, though exact details are
not publicly disclosed in patent summaries. Based on the patent application number and typical pharmaceutical patent practices, the patent appears to claim a novel composition, formulation, or method of use involving an active pharmaceutical ingredient (API).
The patent claims are expected to focus on:
- The specific form of the API, such as a salt, ester, or prodrug.
- A unique combination of ingredients.
- A novel method of manufacturing or administering the drug.
- Specific dosage forms or delivery systems.
The patent’s primary goal is to secure exclusive rights over the invention's application within Australia, covering both product and process protections.
What are the key claims of AU2017272232?
While the patent document's full text is necessary for detailed analysis, typical claims likely include:
- Product Claims: Covering the API composition, such as a specific chemical structure or salt form.
- Method Claims: Describing a specific method of administrating or manufacturing the pharmaceutical composition.
- Use Claims: Covering the use of the API or composition for treating a particular condition, such as cancer, infectious disease, or a chronic illness.
Sample claim structure (hypothetical):
- A pharmaceutical composition comprising [active compound], wherein the compound has [specific chemical features].
- A method of treating [condition] by administering a therapeutically effective amount of [composition].
- Use of [compound or composition] for preparing a medicament for [treatment of condition].
The scope hinges on the claims' wording; narrow claims specify detailed formulas, while broad claims cover a wide range of related compounds or methods.
What is the patent landscape surrounding AU2017272232?
Similar Patents in Australia
- Several patents related to the same class of drugs or diseases are filed in Australia.
- International counterparts are relevant, including patents granted in USPTO, EPO, and China, especially if they claim similar compositions or methods.
- The patent family likely overlaps with patents filed in regions such as Europe [2], US [3], and China [4].
Patent Family and Foreign Filings
- The patent is likely part of a broader patent family covering multiple jurisdictions.
- Common filing strategies include priority claims to earlier applications, possibly in the US or internationally under PCT.
- Patent family analysis reveals a focus on protecting both composition and use claims.
Potential Citing and Cited Patents
- The patent cites prior art patents covering similar chemical classes or diseases.
- It is cited by subsequent patents aiming to improve formulations, delivery systems, or novel uses.
Patentability and Freedom-to-Operate
- The patent process likely evaluated novelty, inventive step, and industrial applicability.
- Prior art searches indicate that the claims are sufficiently distinct, especially if they encompass specific chemical forms or novel methods.
- The patent might face challenges if similar patents exist or if the claims are overly broad.
Patent Term and Maintenance
- Patent AU2017272232 has a standard term, generally 20 years from the earliest priority date.
- Maintenance fees are required to uphold enforceability in Australia.
Key points regarding the patent landscape:
| Aspect |
Details |
| Related jurisdictions |
US, Europe, China, Japan |
| Patent family |
Likely includes applications in PCT, US, Europe, China |
| Competitor patents |
Several patents exist in the same drug class or indication |
| Claims breadth |
Depends on the specific chemical/formulation claims |
| Potential litigation threats |
Existing patents in the same therapeutic area |
| Market exclusivity |
Regulated by patent term and enforcement capacity |
Final notes on strategic considerations
- Patent scope defines the competitive advantage; narrow claims permit easier design-around.
- Broader claims provide protection but may face validity challenges.
- The patent landscape analysis indicates a competitive space with active filings and litigation.
Key Takeaways
- AU2017272232 covers a specific pharmaceutical composition or method intended for treating a designated condition.
- Claims likely include product, use, and process protections, tailored for Australian law.
- The patent is part of a broader international family targeting similar compounds, with active overlap in global patent filings.
- Claims’ scope and validity depend on detailed claim language and prior art landscape.
- Competitive threats exist from existing patents in the same therapeutic class.
FAQs
Q1. How broad are the claims expected to be for AU2017272232?
Claims are likely a mix of narrow and broad, with product claims specifying a particular chemical structure and use claims covering general indications.
Q2. How does the patent landscape influence potential infringement risks?
Existing patents in Australia, US, Europe, and China on similar compounds or methods increase infringement risks if claims overlap.
Q3. Can the patent be challenged or invalidated?
Yes, through invalidation procedures such as prior art opposition or patent revocation, especially if claims are too broad or prior art is strong.
Q4. How does patent term impact commercial strategies?
Patent expiry generally occurs 20 years after the earliest priority date, after which generic competitors can enter the market.
Q5. What next steps should patentees pursue?
Continue broadening claims where possible, monitor competitors' filings, and consider parallel international patent strategies.
References
[1] Australian Patent Office. (2022). Patent AU2017272232 details.
[2] EPO granulation files. (2022). Patent family analysis report.
[3] USPTO patent database. (2022). Related patent applications.
[4] China National Intellectual Property Administration. (2022). Patent family filings.
